Premium
Risk Assessment in Regulatory Policy Making for Human and Veterinary Public Health
Author(s) -
Lathers Claire M.
Publication year - 2002
Publication title -
the journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.92
H-Index - 116
eISSN - 1552-4604
pISSN - 0091-2700
DOI - 10.1177/009127002401102768
Subject(s) - risk assessment , veterinary drugs , public health , antibiotic resistance , food safety , environmental health , business , production (economics) , medicine , enterococcus faecium , microbiology and biotechnology , risk analysis (engineering) , veterinary medicine , antibiotics , biology , computer science , economics , computer security , nursing , macroeconomics , pathology
Risk assessment is the method of systematically identifying and assessing factors that influence the probability and consequences of a negative event occurring. One responsibility of veterinary medicine is to protect animal and human health. Food animal production uses antibiotics to enhance production. Regulators evaluate new production technology to ensure animal safety and safe, edible products and to make public policy decisions by assessing risks/benefits. The U.S. Food and Drug Administration, Center for Veterinary Medicine's (CVM's) first risk assessment addressed the potential human health impact of campylobacter effects associated with the use of fluoroquinolines in food‐producing animals. CVM used the Monte Carlo method to estimate risk by probability distributions that reflect the uncertainty and variability in the data used for the assessment. Enterococci faecium is a species more likely to be resistant to antibiotics of last resort. Effective control of multidrug‐resistant enterococci will require a better understanding of the transfer of E. faecium from animals to humans and the interaction between E. faecium, the hospital environment, and humans; prudent antibiotic use; better contact isolation in hospitals; and better surveillance. CVM will model these factors in a second, more complex risk assessment designed to examine the indirect transfer of resistance from animals to humans. Use of risk assessments allows researchers, the industry, regulatory authorities, and educators to make better policy decisions regarding antimicrobial use in food animals and humans and the development of resistance. Today the question of whether the use of antimicrobials for growth enhancement in food animals should or should not be terminated for the benefit of human health remains unresolved.